3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
6
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Anus Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Neoplasms by Site
1
Neoplasm Recurrence, Local
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Disease
1
Dermatitis
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
Carboplatin
4
Pemetrexed
3
pembrolizumab
2
patritumab
2
osimertinib
2
Sunitinib
2
Standard of Care
2
Paclitaxel
2
Irinotecan
2
Cisplatin
2
Ascorbic Acid
2
valrubicin
1
pralsetinib
1
palbociclib
1
napabucasin
1
linifanib
1
genexol-PM
1
dostarlimab
1
alectinib
1
Watchful Waiting
1
Sorafenib
1
Ramucirumab
1
Patient Reported Outcome Measures
1
Mitomycin
1
KRN-330
1
Interleukin-2
1
Indocyanine Green
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Site
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts